Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Prueba basada en análisis de sangre para diagnóstico del cáncer de mama

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20161024001
Publicado:
09/11/2016
Caducidad:
09/11/2017
Resumen:
Una universidad alemana ha desarrollado una prueba basada en análisis de sangre para la detección del cáncer de mama y sus fases precancerosas. En comparación con la mamografía actual, este procedimiento médico solo requiere una muestra de sangre. La prueba se basa en el grado e intensidad de metilación de los sitios CpG de los promotores de biomarcadores del cáncer de mama en fase temprana (genes SPAG6, NKX2-6 y PER1). Estos tres genes combinados ofrecen la oportunidad de realizar una prueba sencilla para la detección del cáncer de mama a partir de una muestra de sangre del paciente (biopsia líquida). La universidad busca socios con el fin de establecer acuerdos de licencia.

Details

Tittle:
Blood-based diagnostic test for breast cancer
Summary:
A German university developed a blood-based test to detect breast cancer and its pre-cancerous stages. Compared to the current standard mammography this medical procedure just requires a blood sample. The university offers a license agreement.
Description:
Breast cancer is the most common type of cancer of women in industrial countries, accounting for fifteen percent of cancer-related deaths. Early detection of breast cancer, most favorably in a pre-cancerous (in situ) state is critical for the course of the disease and its outcome. Currently, mammography screening is the standard method of medical prevention. However, the compliance among women invited for mammography is low and varies from 20 to 89 percent depending on country and age group. Similar to colorectal cancer prevention by coloscopy, a much easier and less stressful examination method might find stronger compliance.

Researchers of a German university have developed a blood-based diagnostic test for breast cancer and its pre-cancerous stages, based on the grade and intensity of CpG promoter methylation of early breast cancer biomarkers, i.e. the genes SPAG6, NKX2-6 and PER1 (the "SNP panel"). Combined, these three genes provide an opportunity to easily test for breast cancer, starting from a patient´s blood sample (liquid biopsy). It is very likely that a blood-based test would increase compliance of women to participate in medical prevention of breast cancer. In addition, this concept may allow to broaden prevention to elderly women (>70 years) who currently are not invited to mammography screening.

The university offers a license agreement to companies that provide diagnostic services on sample materials from patients.
Advantages and Innovations:
A blood-based test to detect breast cancer is an easy to perform pre-screen to detect breast cancer and is far more comfortable way for women to pass the prevention. Compared to the current standard procedure to detect breast cancer (a mammography) the herewith presented invention is likely to be of much higher compliance to women and increase the screening participation.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European Patent Office

Partner sought

Type and Role of Partner Sought:
The university offers a license agreement to companies/institutes that provide diagnostic services to examine sample materials from patients.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis